May 19, 2020

GiveMatcher Co-Founder on Corporate Social Responsibility and the Joy of Giving Back

charity
stakeholder
Leadership
corporate social responsibility
We Photo Booth You
6 min
GiveMatcher Co-Founder on Corporate Social Responsibility and the Joy of Giving Back

Read other articles from our July issue of Business Review Australia here.

What would it take for you to give up your job? For Franck Demoiseau, it was about finding purpose in his life. About four months ago, Demoiseau was the chief operating officer of BNP Paribas, a French bank with a global presence. Now, the online charitable donation venue Givematcher he co-founded is in the second phase of its launch.

In this exclusive interview, Business Review Australia gets the inside look at this innovative venture, and delves into the importance of corporate social responsibility.

What led you to leave a C-level banking job to found Givematcher?

I had a need for more meaning and purpose, and had been thinking for a long time about becoming more involved with the for-purpose sector. I had thought about joining charity boards, or working for a charity, but decided that starting a social venture able to be relevant to the entire sector would allow me to maximise my social impact. The concept behind Givematcher struck a chord with me as I sensed it would make a massive difference to any charity by assisting them with a real area of need like their fundraising, which would then enable them to focus more on servicing their cause. Furthermore, the other stakeholders - companies and private donors - would also derive great benefits, increasing both the impact of Givematcher and its chance of success. Here was an idea that had the potential to do a lot of good, and I asked myself “how many times in one's life does one have an opportunity to make a real difference?”

What exactly is Givematcher, and how does it reward the different stakeholders?

Givematcher is a charity portal that is helping charities all over Australia raise more money more easily online, using a unique new concept we call Open Matched Giving (OMG): donors donate to a charity and their donation is matched by one of our socially minded participating companies (not necessarily their employer).

Charities get new donors, receive higher donations due to the matching and reduce their cost of fundraising. Companies are rewarded with cost-effective marketing and brand building, particularly when they opt to offer to match the donations of their existing customers, potential customers and staff. Companies are also delighted that their philanthropy budget is leveraged by donations from private donors, and consider that this is a much better way to provide financial support to their chosen causes and to increase their social impact. Donors, the third stakeholder, receive a heartfelt leveraging effect for their donation. The overwhelming majority of donors have never had this option and are enjoying this benefit for the very first time in their life.

What has the response been so far to this innovative charitable platform?

Being only three months old, this is still early days! We have had to follow a very specific implementation sequence, consisting of three phases: firstly, bring on board the charities, then the companies, and finally the public. The reaction from the charities has been stunning, with around 100 charities signing up in the first three months, including many of the major charities (Heart Foundation, Mission Australia, Salvation Army, St Vincent de Paul Society, The Leukaemia Foundation, Guide Dogs and many others). Charities love that this new channel is allowing them to gain new donors and raise more funds in the most cost-effective way. They are also delighted that they can go to companies and offer them new value in return for their financial support, by asking for matching donations instead of donations or grants.

We have just started the second phase and are meeting with companies. The early feedback is excellent. So far, 10 companies have joined and many more are in the pipeline. The marketing and social recognition benefits are strong drivers, as is the opportunity to leverage their social impact and to become even more helpful to the community. We have not yet contacted donors, as this will be the third phase, but in spite of this, we are already seeing exponential donation flows, as charities and companies are driving donors to our portal.

How do you see Givematcher growing and evolving in the future?

We shall quickly grow to hundreds of charities and companies, and likely beyond this, as the benefits to charities and companies are very compelling. Regarding donors, early signs are good, and we believe donations will continue their strong growth. It just makes good sense and we simply ask ourselves: why wouldn't everyone choose to donate this way? If anyone cares about a charity, they will want to ensure that more of their generous funds go to the cause itself, and they will want to be matched if this option is made available to them. What we really hope to be able to achieve is for this low-cost way of raising funds to replace some of the more expensive archaic ways such face-to-face (in the street), over the phone or direct mail, which can eat up as much as 30 to 50 percent of the funds, are quite intrusive, and in the end, are perhaps even counterproductive.

How important would you say it is for a company to get involved with a charity or charities? What are the benefits? Do you see any drawbacks for the company?

In my view, it is nothing short of necessary for any company to provide at least moderate financial support to charities. Yes, there are too many charities, and there are surely efficiencies to be had (one of these being with fundraising methods), but a great many charities are indispensable and faced with increasing demand for their vital services. Many receive little or no government funding, and hence rely on funding from companies (and individuals), so I believe there to be a moral obligation for companies to give back. Thankfully, many companies are already doing this.

It is also very important from a Corporate Social Responsibility standpoint to assist the communities within which companies are deriving profits. Consumers, staff and the public at large are unforgiving critics when it comes to this (particularly Gen Y’s), and it is well accepted that a company’s social responsibility and actual support for social causes are key deciding factors in brand selection, as well as essential factors in staff engagement and retention. Companies “do well by doing good” and it makes great business sense for companies to be visible in their support of charities. I don't see a lot of drawbacks. Compared with company revenues and overall costs, this is only a small cost. At the end of the day, we just need to remember that people are watching our companies, and they are busy judging.

What leadership advice would you give the current c-level executives of Australia?

Research clearly shows that companies that are doing social good are benefiting. It is not just simply something that makes company executives feel good about themselves. When done right, it is a powerful, proven way to drive more business and to build brand awareness and engagement. It drives consumers to select their brand, appeals to existing customers, builds staff engagement and helps attract and retain talent.

My leadership advice to our c-level executives is to take advantage of this tremendous win-win opportunity to help the community and create shareholder value. This can be done by directing more funds to support the community, or by using a platform like Givematcher to drive additional value and social good from your company’s existing philanthropy budget, or preferably both. You get to feel good about yourself as well!

Share article

Jun 13, 2021

Seo JungJin: Who is EY’s World Entrepreneur of 2021?

EY
entrepreneurs
Leadership
celltrion
Kate Birch
3 min
From just US$45,000 capital in 2003 to a world-leading biopharma giant with revenues of US$1.69bn today, Seo JungJin is crowned EY World Entrepreneur 2021

Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.

Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.

JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.

Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.

Why was JungJin crowned King Entrepreneur?

A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.

The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.

According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.

Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.

“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”

How did JungJin get there?

JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.

Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.

And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.

With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.

“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”

 

Share article